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This dataset provides a clinical description along with extensive
biochemical and molecular characterization of a patient with a
homozygous mutation in PEX16 with an atypical phenotype. This
patient described in Molecular Genetics and Metabolism Reports
was ultimately diagnosed with an atypical peroxisomal disorder
on exome sequencing. A clinical timeline and diagnostic summary,
results of an extensive plasma and ﬁbroblast analysis of this
patient's peroxisomal proﬁle is provided. In addition, a table of
additional variants from the exome analysis is provided.
& 2016 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Genomics
ore speciﬁc sub-
ject areaPeroxisomal Disordersype of data Table 1 – Biochemical analytes
Table 2 – Variants from exome sequencingis an open access article under the CC BY license
/j.ymgmr.2015.09.001
ular and Human Genetics, BCM, Houston, TX, 77030TX, USA.
. Wangler).
HD
E
E
D
Table 1
Comprehensive plasma and
Analyte
Phytanic acid oxidation
(% mean of control
value)
Pristanic acid oxication
(% mean of control
Value)
C. Bacino et al. / Data in Brief 6 (2016) 722–727 723Fig. 1 – Clinical timeline and diagnostic workup
Fig. 2 – Biochemical analytesow data was
acquiredBlood samples and a skin biopsy were obtained from the patient. DNA, plasma
and cultured ﬁbroblasts were analyzed in the context of the patient’s diagnostic
course. LC–MS/MS, Enzyme activity using radioactive substrates, colorimetric
assays, next-generation sequencing.ata format Analyzed datasets, Excel, Tif ﬁles.
xperimental
factorsUnique genotype (n¼1)xperimental
featuresPlasma samples and cultured ﬁbroblast from a skin biopsy were used for per-
oxisomal biochemical analysis. Genomic DNA was utilized for whole-exome
sequencing.ata source
locationHouston Texasata accessibility Date is included with this articleD
Value of the data
 A proﬁle of a patient with an atypical peroxisomal biogenesis disorder which can be compared
with other patient's with these phenotypes.
 Clinical review of diagnostic considerations for atypical peroxisomal biogenesis disorders.
 Comprehensive set of functional consequences of F332del allele of PEX16.1. Data
See Table 1.
1. Plasma VLCFA – plasma was collected at ages 10 years, 11 years and 22 years for VLCFA analysis.
Values shown in ug/ml. C24/C22 and C26/C22 ratios shown. Z-scores of the patient's sample
measurment as compared to a set of normal controls shown.
2. Fibroblast VLCFA – patient ﬁbroblasts were cultured and analyzed for VLCFA analysis. Values shown
are in mg/mg protein. Z-scores of the patient's sample measurment as compared to a set of normal
controls shown.
3. Catalase Distribution – cultured cells were analyzed for Catalase Distribution (expressed in %
soluble). A Z-score of the patient's sample is shown.
4. Plasmalogen synthesis assay from radiolabel enzyme assay is shown.
5. Plasma pipecolic acid (expressed in mmole/L).
6. Lyso-PC – LC MS/MS of lysophospholipids for the patient's blood sample at 22 years.
7. 14C oxidation assays for Phytanic and Pristanic acid (in % of the mean of controls) shown.ﬁbroblast biochemical analysis.
Control
ﬁbroblasts
Zellweger
syndrome
Patient@22
years
100 5.7 73
100 4.9 156.9
Table 2
Candidate variants table from Whole-exome sequencing.
Gene Postion Isoform Nucleotide Protein Zygosity Disease Disease
inheritance
Comment
CTC1 Ch17:8134658 NM_025099 c.2605C4T p.
Q869X
Het Cerebroretinal
microangio-
pathy with cal-
ciﬁcations and
cysts
AR Father also
heterozygous
SYNE1 Chr6:152730222 NM_033071 c.6542C4T p.
T2181I
Het Spinocerebellar
ataxia, auto-
somal recessive
8
AR Mother also
heterozygous
C5orf42 Chr5: 37185062 NM_023073 c.4309A4G p.
I1437V
Het Joubert
syndrome
AR Novel variant
CLN3 CH16:28493901 uc010vcx.1 c.583C4G p.
P195A
Het Ceroid
lipofuscinosis
AR rs146839771
VPS13A Chr9:79902873 NM_033305 c.3356G4A p.
G1119E
Het Chor-
eoacanthocy-
tosis
AR rs144358567
PSAP Ch10:73588801 NM_002778 c.409C4G p.L137V Het Combined SAP
deﬁciency
AR Novel variant
MAN1B1 Ch9: 140002934 NM_016219 c.1991C4T p.
T664M
Het Mental retar-
dation, auto-
somal recessive
15
AR Reported in
ESP5400 and
or Thousand
Genomes
NPC1 Chr18:21166261 NM_000271 c.47G4A p.C16Y Het Niemann–Pick
disease, type D
AR Novel variant
BRAT1 Chr7:2579447 NM_152743 c.1471G4A p.
G491S
Het Rigidity and
multifocal sei-
zure syndrome,
lethal neonatal
AR Father also
heterozygous
BRAT1 Chr7: 2582935 NM_152743 c.826G4A p.
D276N
Het Rigidity and
multifocal sei-
zure syndrome,
lethal neonatal
AR Mother het-
erozygous,
rs146546197
PEX16 Chr11:45931818 NM_004813 c.995_997delTCT p.
F332del
Hom Zellweger syn-
drome, com-
plementation 9
AR Novel variant,
both parents
heterozygous
Fig. 1. Clinical timeline for the patient.
C. Bacino et al. / Data in Brief 6 (2016) 722–727724List of variants in disease-causing genes including heterozygous and homozygous variants which
were veriﬁed by Sanger sequencing. The Gene, position, speciﬁc isoform, nucleotide, protein change
(predicted), and zygosity are shown. AR¼Autosomal recessive. Comments contain segregation
information from the parents or other populations (Table 2). A clinical and diagnostic timeline for
the patient showing clinical events and gene diagnostic tests. WES¼Whole-exome sequencing
(Figs. 1 and 2).
Fig. 2. Peroxisomal biochemical studies. (A) C26:0 Lyso PC measured by LC–MS–MS for the Patient's plasma compared to
Normals and other disease populations. (B) Catalase Distributionin cultured ﬁbroblasts (expressed as % soluble). (C) Bile acid
measurements in pmoles/10ml plasma for the Patient, controls and other disease populations.
C. Bacino et al. / Data in Brief 6 (2016) 722–727 7252. Experimental design, materials and methods
2.1. Ethics statement
Informed consent for the research and for publication was obtained prior to participation for the
subject who was recruited under an Institutional Review Board approved protocol at Baylor College of
Medicine.2.2. Peroxisomal biochemical studies
Plasma samples and cultured ﬁbroblast from a skin biopsy were used for peroxisomal biochemical
analysis.
– Plasma pipecolic acid was measured by electron capture negative ion mass fragmentography [1].
– Very-long-chain fatty acid levels and total lipid fatty acid proﬁle were measured as described [2,3].
– The plasmalogen assay was performed using C14 radioactivity incorporation and H3 counts to
measure microsomal plasmalogen steps [4].
C. Bacino et al. / Data in Brief 6 (2016) 722–727726– Fibroblast oxidation assays were performed using radioactive substrates to assay enzyme activity
[5,6].
– Measurement of C26:0-lyso-PC was performed as described [7] and bile acid quantitation was
performed by tandem mass spectrometry [8].
– Catalase distribution in cultured cells was performed and quantiﬁed (% soluble catalase) [9,10].2.3. Whole-exome capture, sequencing and data analysis
The patient underwent WES through the Whole Genome Laboratory (https://www.bcm.edu/
research/medical-genetics-labs/index.cfm?PMID¼21319) using methods described [11].
– Produced sequence reads were aligned to the GRCh37 (hg19) human genome reference assembly
using the HGSC Mercury analysis pipeline (http://www.tinyurl.com/HGSC-Mercury/). Variants were
determined and called using the Atlas2 [12] suite to produce a variant call ﬁle (VCF [13]).
– High-quality variants were annotated using an in-house developed suite of annotation tools [14].Acknowledgments
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Supplementary data associated with this article can be found in the online version at http://dx.doi.
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[1] R.M. Kok, L. Kaster, A.P. de Jong, B. Poll-The, J.M. Saudubray, C. Jakobs, Stable isotope dilution analysis of pipecolic acid in
cerebrospinal ﬂuid, plasma, urine and amniotic ﬂuid using electron capture negative ion mass fragmentography, Clin.
Chim. Acta 168 (2) (1987) 143–152.
[2] A.B. Moser, N. Kreiter, L. Bezman, S. Lu, G.V. Raymond, S. Naidu, H.W. Moser, Plasma very long chain fatty acids in 3,000
peroxisome disease patients and 29,000 controls, Ann. Neurol. 45 (1) (1999) 100–110.
[3] S.A. Lagerstedt, D.R. Hinrichs, S.M. Batt, M.J. Magera, P. Rinaldo, J.P. McConnell, Quantitative determination of plasma c8–
c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders, Mol. Genet. Metab. 73 (1) (2001)
38–45.
[4] A. Roscher, B. Molzer, H. Bernheimer, S. Stockler, I. Mutz, F. Paltauf, The cerebrohepatorenal (Zellweger) syndrome: an
improved method for the biochemical diagnosis and its potential value for prenatal detection, Pediatr. Res. 19 (9) (1985)
930–933.
[5] A. Poulos, Diagnosis of Refsum's disease using [1-14C]phytanic acid as substrate, Clin. Genet. 20 (4) (1981) 247–253.
[6] R.J. Wanders, S. Denis, J.P. Ruiter, R.B. Schutgens, C.W. van Roermund, B.S. Jacobs, Measurement of peroxisomal fatty acid
beta-oxidation in cultured human skin ﬁbroblasts, J. Inherit. Metab. Dis. 18 (Suppl 1) (1995) S113–S124.
[7] W.C. Hubbard, A.B. Moser, A.C. Liu, R.O. Jones, S.J. Steinberg, F. Lorey, S.R. Panny, R.F. Vogt Jr., D. Macaya, C.T. Turgeon,
S. Tortorelli, G.V. Raymond, Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined
liquid chromatography-tandem mass spectrometric (LC–MS/MS) method, Mol. Genet. Metab. 97 (3) (2009) 212–220.
[8] D.W. Johnson, H.J. ten Brink, R.C. Schuit, C. Jakobs, Rapid and quantitative analysis of unconjugated C(27) bile acids in
plasma and blood samples by tandem mass spectrometry, J. Lipid Res. 42 (1) (2001) 9–16.
[9] M.C. McGuinness, A.B. Moser, B.T. Poll-The, P.A. Watkins, Complementation analysis of patients with intact peroxisomes
and impaired peroxisomal beta-oxidation, Biochem. Med. Metab. Biol. 49 (2) (1993) 228–242.
[10] P.A. Watkins, M.C. McGuinness, G.V. Raymond, B.A. Hicks, J.M. Sisk, A.B. Moser, H.W. Moser, Distinction between perox-
isomal bifunctional enzyme and acyl-CoA oxidase deﬁciencies, Ann. Neurol. 38 (3) (1995) 472–477.
C. Bacino et al. / Data in Brief 6 (2016) 722–727 727[11] J.R. Lupski, C. Gonzaga-Jauregui, Y. Yang, M.N. Bainbridge, S. Jhangiani, C.J. Buhay, C.L. Kovar, M. Wang, A.C. Hawes, J.
G. Reid, C. Eng, D.M. Muzny, R.A. Gibbs, Exome sequencing resolves apparent incidental ﬁndings and reveals further
complexity of SH3TC2 variant alleles causing Charcot–Marie–Tooth neuropathy, Genome Med. 5 (6) (2013) 57.
[12] P. Danecek, A. Auton, G. Abecasis, C.A. Albers, E. Banks, M.A. DePristo, R.E. Handsaker, G. Lunter, G.T. Marth, S.T. Sherry,
G. McVean, R. Durbin, The variant call format and VCFtools, Bioinformatics 27 (15) (2011) 2156–2158.
[13] M.N. Bainbridge, W. Wiszniewski, D.R. Murdock, J. Friedman, C. Gonzaga-Jauregui, I. Newsham, J.G. Reid, J.K. Fink, M.
B. Morgan, M.C. Gingras, D.M. Muzny, L.D. Hoang, S. Yousaf, J.R. Lupski, R.A. Gibbs, Whole-genome sequencing for opti-
mized patient management, Sci. Transl. Med. 3 (87) (2011) 87re3.
[14] A. Untergasser, I. Cutcutache, T. Koressaar, J. Ye, B.C. Faircloth, M. Remm, S.G. Rozen, Primer3 – new capabilities and
interfaces, Nucleic Acids Res. 40 (15) (2012) e115.
